1. Home
  2. ASAN vs DMRA Comparison

ASAN vs DMRA Comparison

Compare ASAN & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

HOLD

Current Price

$5.86

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$23.99

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASAN
DMRA
Founded
2008
2011
Country
United States
United States
Employees
N/A
7
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ASAN
DMRA
Price
$5.86
$23.99
Analyst Decision
Hold
Buy
Analyst Count
14
2
Target Price
$12.46
$43.00
AVG Volume (30 Days)
6.8M
284.6K
Earning Date
06-02-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
27.93
N/A
EPS
N/A
N/A
Revenue
$790,806,000.00
N/A
Revenue This Year
$10.19
N/A
Revenue Next Year
$7.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.25
N/A
52 Week Low
$5.38
$16.50
52 Week High
$19.00
$28.76

Technical Indicators

Market Signals
Indicator
ASAN
DMRA
Relative Strength Index (RSI) 41.62 45.95
Support Level $5.87 $23.64
Resistance Level $6.78 $28.00
Average True Range (ATR) 0.40 1.83
MACD -0.08 -0.18
Stochastic Oscillator 13.17 44.18

Price Performance

Historical Comparison
ASAN
DMRA

About ASAN Asana Inc.

Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: